

# Mansun Law

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6671060/mansun-law-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72  
papers

4,536  
citations

34  
h-index

67  
g-index

79  
ext. papers

5,327  
ext. citations

10.2  
avg, IF

5.3  
L-index

#	Paper	IF	Citations
72	Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. <i>Cell Reports</i> , <b>2022</b> , 39, 110859	10.6	2
71	A structured RNA motif locks Argonaute2:miR-122 onto the 5' end of the HCV genome. <i>Nature Communications</i> , <b>2021</b> , 12, 6836	17.4	2
70	An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. <i>Gastroenterology</i> , <b>2021</b> ,	13.3	2
69	Antibody Responses in Hepatitis C Infection. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2021</b> , 11,	5.4	4
68	Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. <i>Immunity</i> , <b>2021</b> , 54, 781-796.e4	32.3	10
67	Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy.. <i>Antiviral Therapy</i> , <b>2021</b> , 26, 3-8	1.6	1
66	Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro. <i>Proceedings (mdpi)</i> , <b>2020</b> , 50, 5	0.3	
65	Into the Unknown: A Chemical Biology Approach Provides Mechanistic Insight into HCV Entry. <i>Cell Chemical Biology</i> , <b>2020</b> , 27, 767-769	8.2	
64	Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. <i>Science Advances</i> , <b>2020</b> , 6, eaaz6225	14.3	23
63	Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development. <i>Gastroenterology</i> , <b>2020</b> , 158, 1058-1071.e6	13.3	18
62	An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. <i>Science Advances</i> , <b>2020</b> , 6, eabb5642	14.3	9
61	Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model. <i>ACS Medicinal Chemistry Letters</i> , <b>2020</b> , 11, 2428-2432	4.3	2
60	Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10039-10047	11.5	22
59	V1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. <i>Current Opinion in Virology</i> , <b>2019</b> , 34, 149-159	7.5	51
58	Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 68-79	7	10
57	Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. <i>Nature Biomedical Engineering</i> , <b>2019</b> , 3, 806-816	19	43
56	Probing the Antigenicity of HCV Envelope Glycoproteins by Phage Display Antibody Technology. <i>Methods in Molecular Biology</i> , <b>2019</b> , 1911, 381-393	1.4	

55	Simultaneous Quantification of Hepatitis C Virus Envelope Glycoproteins E1 and E2 by Dual-Color Fluorescence Immunoblot Analysis. <i>Methods in Molecular Biology</i> , <b>2019</b> , 1911, 295-304	1.4	
54	Detection of Antibodies to HCV E1E2 by Lectin-Capture ELISA. <i>Methods in Molecular Biology</i> , <b>2019</b> , 1911, 421-432	1.4	4
53	Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). <i>Methods in Molecular Biology</i> , <b>2019</b> , 1911, 441-450	1.4	12
52	Genetic and structural insights into broad neutralization of hepatitis C virus by human V1-69 antibodies. <i>Science Advances</i> , <b>2019</b> , 5, eaav1882	14.3	46
51	Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	14
50	The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1315	8.4	31
49	Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus. <i>Nano Letters</i> , <b>2018</b> , 18, 7832-7838	11.5	22
48	Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 7569-7574	11.5	8
47	Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. <i>MBio</i> , <b>2017</b> , 8,	7.8	22
46	Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006214	7.6	21
45	Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	25
44	Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006735	7.6	46
43	Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. <i>Hepatology</i> , <b>2016</b> , 64, 1881-1892	11.2	48
42	Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 12768-12773	11.5	48
41	Low-Cost Peptide Microarrays for Mapping Continuous Antibody Epitopes. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1352, 67-83	1.4	9
40	Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. <i>Liver Transplantation</i> , <b>2016</b> , 22, 324-32	4.5	12
39	Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody 1GH526. <i>Journal of Molecular Biology</i> , <b>2015</b> , 427, 2617-28	6.5	32
38	Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. <i>Current Opinion in Virology</i> , <b>2015</b> , 11, 148-57	7.5	34

37	A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status. <i>Molecular Therapy</i> , <b>2015</b> , 23, 1734-1747	11.7	25
36	Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. <i>Scientific Reports</i> , <b>2015</b> , 5, 12501	4.9	40
35	Optimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes. <i>Journal of Immunological Methods</i> , <b>2014</b> , 402, 35-42	2.5	10
34	Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. <i>Journal of Virology</i> , <b>2014</b> , 88, 10459-71	6.6	35
33	Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. <i>Hepatology</i> , <b>2014</b> , 60, 1551-62	11.2	60
32	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. <i>Virology</i> , <b>2014</b> , 458-459, 190-208	3.6	14
31	Broadly neutralizing antibodies abrogate established hepatitis C virus infection. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 254ra129	17.5	161
30	Completion of the entire hepatitis C virus life cycle in genetically humanized mice. <i>Nature</i> , <b>2013</b> , 501, 237-41	50.4	184
29	Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. <i>Hepatology</i> , <b>2013</b> , 58, 1587-97	11.2	33
28	Hepatitis C virus E2 envelope glycoprotein core structure. <i>Science</i> , <b>2013</b> , 342, 1090-4	33.3	300
27	Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. <i>Journal of Virology</i> , <b>2012</b> , 86, 13085-8	6.6	67
26	Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 9499-504	11.5	113
25	Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. <i>Vaccine Journal</i> , <b>2012</b> , 19, 1027-37		17
24	Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. <i>Journal of Virology</i> , <b>2012</b> , 86, 11956-66	6.6	30
23	Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 6205-10	11.5	256
22	A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). <i>PLoS ONE</i> , <b>2012</b> , 7, e38028	3.7	24
21	A genetically humanized mouse model for hepatitis C virus infection. <i>Nature</i> , <b>2011</b> , 474, 208-11	50.4	298
20	Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. <i>Chemistry and Biology</i> , <b>2011</b> , 18, 1453-62		40

19	Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. <i>Journal of Virology</i> , <b>2010</b> , 84, 10999-1009	6.6	166
18	Acidic residues in the membrane-proximal stalk region of vaccinia virus protein B5 are required for glycosaminoglycan-mediated disruption of the extracellular enveloped virus outer membrane. <i>Journal of General Virology</i> , <b>2009</b> , 90, 1582-1591	4.9	23
17	Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. <i>Nature Medicine</i> , <b>2008</b> , 14, 25-7	50.5	466
16	Antibodies against viruses: passive and active immunization. <i>Current Opinion in Immunology</i> , <b>2008</b> , 20, 486-92	7.8	38
15	Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. <i>Journal of Virology</i> , <b>2007</b> , 81, 4272-85	6.6	84
14	Ligand-induced and nonfusogenic dissolution of a viral membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 5989-94	11.5	95
13	Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. <i>Nature Medicine</i> , <b>2006</b> , 12, 1310-5	50.5	92
12	Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. <i>Journal of General Virology</i> , <b>2005</b> , 86, 1279-1290	4.9	110
11	Comparing antigenicity and immunogenicity of engineered gp120. <i>Journal of Virology</i> , <b>2005</b> , 79, 12148-63.6	6.6	86
10	An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. <i>Journal of General Virology</i> , <b>2005</b> , 86, 991-1000	4.9	55
9	Studying the binding and entry of the intracellular and extracellular enveloped forms of vaccinia virus. <i>Methods in Molecular Biology</i> , <b>2004</b> , 269, 187-204	1.4	19
8	Yaba-like disease virus protein Y144R, a member of the complement control protein family, is present on enveloped virions that are associated with virus-induced actin tails. <i>Journal of General Virology</i> , <b>2004</b> , 85, 1279-1290	4.9	15
7	The exit of vaccinia virus from infected cells. <i>Virus Research</i> , <b>2004</b> , 106, 189-97	6.4	90
6	Vaccinia virus motility. <i>Annual Review of Microbiology</i> , <b>2003</b> , 57, 323-42	17.5	83
5	Vaccinia virus cores are transported on microtubules. <i>Journal of General Virology</i> , <b>2003</b> , 84, 2443-2458	4.9	85
4	Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. <i>Journal of General Virology</i> , <b>2002</b> , 83, 209-222	4.9	62
3	The formation and function of extracellular enveloped vaccinia virus. <i>Journal of General Virology</i> , <b>2002</b> , 83, 2915-2931	4.9	368
2	Antibody neutralization of the extracellular enveloped form of vaccinia virus. <i>Virology</i> , <b>2001</b> , 280, 132-43.6	4.9	74

- 1 Vaccinia virus utilizes microtubules for movement to the cell surface. *Journal of Cell Biology*, **2001**, 154, 389-402 73 181